BRIEF—Pfizer's Abrilada granted interchangeability for Humira

US pharma giant Pfizer today announced that the US Food and Drug Administration (FDA) has designated Abrilada (adalimumab-afzb) as an interchangeable biosimilar to AbbVie’s mega-blockbuster Humira (adalimumab).

The interchangeable designation applies to all approved indications of Abrilada, including certain patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.

Abrilada will be available later this year at two price points, with the goal of achieving the broadest possible access for patients.

Starting in late October 2023, Abrilada will be available at a list price (Wholesale Acquisition Cost) 5% below the Humira list price.

Later in 2023, Abrilada will be available at a second list price 60% below the Humira list price.